All Publications

Lipid testing in patients with rheumatoid arthritis and key cardiovascular-related comorbidities
Annual lipid testing is recommended to reduce morbidity and mortality for patients with rheumatoid arthritis and comorbid cardiovascular disease, diabetes,…
5 year colorectal cancer outcomes in a large negative CT colonography screening cohort
In this study co-authored by Dr. Jennifer Weiss, the authors examined the 5-year incidence of clinically presenting colorectal cancers following…
Monitoring diabetes in patients with and without rheumatoid arthritis
Diabetes mellitus is an important predictor of mortality in patients with rheumatoid arthritis (RA), and both diseases increase the risk…
Public reporting helped drive quality improvement in outpatient diabetes care among Wisconsin physician groups
This Health Affairs article by Dr. Maureen Smith et al. examined how physician groups respond to public reporting. The authors…
Mortality by stage for right vs. left-sided colon cancer
In this article by Dr. Jennifer Weiss et al., the authors used SEER-Medicare data to predict all-cause 5-year mortality by…
Minority status and diabetes screening in an ambulatory population
Ethnicity has been identified as a risk factor for type 2 diabetes, as well as increased morbidity and mortality with…
Low frequency of primary lipid screening among Medicare patients with rheumatoid arthritis
Dr. Christie Bartels et al. examined the performance of primary lipid screening in rheumatoid arthritis patients. The retrospective cohort study…
For-profit hospital status and rehospitalizations at different hospitals: an analysis of Medicare data
Dr. Amy Kind and co-authors examined predictors of and payments for rehospitalization at a different hospital among a 5% random…
Why some disabled adults in Medicaid face large out-of-pocket expenses
Marguerite Burns et al. used Medical Expenditure Panel survey data to examine out-of-pocket health care spending for Medicaid enrollees aged…
Amongst eligible patients, age and comorbidity do not predict for dose limiting toxicity from phase I chemotherapy
Dr. Noelle LoConte et al. sought to identify clinical and non-clinical factors which were associated with the development of dose-limiting…